Lexicon Pharmaceuticals (LXRX) Posts Q3 Loss of 6c/Share
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.22 +0.91%
Revenue Growth %: -86.1%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
SFNC, CSBR, MAN, More
Revenue Growth %: -86.1%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
SFNC, CSBR, MAN, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $372 thousand versus the consensus estimate of $600 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Benchmark initiates Synopsys, Cadence with Buy ratings on AI-driven EDA outlook
- GE Aerospace beats estimates, lifts guidance on services growth
- Oakworth Capital posts 14% net income rise in first half 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
